No Data
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
HighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug
HIGHTIDE-B (02511) has completed the patient enrollment for the HTD1801 head-to-head treatment of Dapagliflozin in a phase III clinical trial for type 2 diabetes.
HIGHTIDE-B (02511) announced that the company's independently developed intestinal and hepatic anti-inflammatory and metabolic regulator ursodeoxycholic acid...
HIGHTIDE-B (02511): Gao Liping has been appointed as the joint company secretary.
HIGHTIDE-B (02511) has announced that due to the need to allocate more time to other work arrangements, Yu Li has submitted...
HighTide Therapeutics to Cooperate on Chronic Diseases, Longevity, Anti-Aging With SSY Group
Express News | HighTide Therapeutics - Unit Entered Into Strategic Co-Operation Framework Agreement With Shijiazhuang No. 4 Pharmaceutical
